KTP治疗良性前列腺增生520例临床分析

目的探讨KTP（KTiOPO4,简称KTP）高能磷酸钛氧钾晶体治疗良性前列腺增生的安全性及疗效。方法应用绿激光PVP治疗良性前列腺增生520例,观察手术前后国际前列腺症状评分（International prostate symptom score IPSS）、生活质量评分（Quality of life assessment QOL）、尿流率、手术时间、留置尿管时间、手术并发症等情况。结果本组520例患者,年龄52～94岁,年龄〉80岁141例,占24.12%,前列腺体积25～220ml,其中〈80ml 125例（24.04%）,〉80ml 395例,术前留置尿管216例,留置耻骨上膀胱造瘘管15例。合并心肺等内科疾病265例,前列腺症状评分IPSS平均26分,平均最大尿流率8.6ml/min;本组手术时间20～240分钟,平均82分钟。术后未留置尿管28例,留置尿管例于术后1～5天拔除。拔除尿管测平均最大尿流率14.5ml/min,术后随访2～4月,IPSS评分平均11分,平均最大尿流率达17.8 ml/min。结论绿激光PVP治疗良性前列腺增生患者手术安全性高,操作简单,手术时间短,留置尿管时间短,恢复快,治疗效果满意。     

经尿道汽化切割术治疗前列腺增生

目的:探讨经尿道前列腺汽化切割术治疗前列腺增生的效果。方法:采用经尿道前列腺汽化切割术治疗良性前列腺增生(BPH)253例。结果:253例手术时间平均65min,平均出血量40ml,术后间断冲洗膀胱1～3d。留置导尿管时间平均3～5d。有1例在术中发生尿道电切综合征(TURS),经即时救治后恢复正常,1例术中发生前列腺包膜穿孔,经留置导尿管和膀胱造瘘管后治愈,1例于术后第6d发生急性心肌梗塞死亡。其余病人拔尿管后均排尿通畅,前列腺症状评分与术前相比平均下降16.9分;最大尿流率增加11.5ml/s。结论:经尿道前列腺汽化切割术具有汽化、电切的优点,其疗效与开放手术相似,并有创伤小,并发症少,住院时间短等优点,尤其适应于高危的BPH患者。     

经尿道汽化切割术治疗高危前列腺增生

目的探讨手术治疗高危前列腺增生症的疗效和安全性.方法术前对患者的病情及手术危险性进行评估,并作围手术期充分准备,采用经尿道前列腺汽化切割术治疗,高危前列腺增生症98例.结果98例安全度过围手术期,拔尿管后均排尿通畅.国际前列腺症状评分从术前(25.5±3.5)分,降至术后(5.6±2.3)分,生活质量评分从(5.5±0.5)分降至(1.2±0.5)分,最大尿流率从术前(0～11)ml/s,增加至术后平均16 ml/s,痊愈出院.结论 经尿道前列腺汽化切割具有疗效显著,出血少,安全,适用于高危的前列腺增生患者.     

经尿道前列腺电汽化术治疗前列腺增生症60列体会

目的:探讨电汽化切割治疗前列腺增生症(BPH)的效果。方法:采用经尿道前列腺电汽化术(TUVP)治疗良性前列腺增生60例。结果:平均手术时间60min;平均出血70ml;最大尿流率由术前5.32±2.35ml/s上升至术后的18.5±3.22ml/s;IPSS症状评分术前28.34±3.12,术后降至8.4±2.12(P〈0.05)。结论:经尿道前列腺电汽化切割出血少,手术安全,治疗效果明显,是治疗BPH最有效的治疗方法之一。有利于在基层广发的开展和普及。     

绿激光PVP手术与TURP手术治疗前列腺增生症的对照研究

 目的 评价经尿道前列腺绿激光汽化术(PVP)治疗前列腺增生症的近期疗效.方法 122例<60 g前列腺增生症患者进行非随机的双中心研究,其中PVP手术组71例,TURP手术组51例,比较两组的手术时间、出血量、近期疗效及并发症.结果 两组术后前列腺国际症状评分(IPSS)、生活质量评分(QOL)、最大尿流率和残余尿量均较术前明显改善(P<0.05),PVP组平均术中出血量、留置尿管时间及近期并发症明显小于TURP组(P＜0.01).结论 绿激光PVP手术与TURP手术治疗<60 g前列腺增生症近期疗效相似,且绿激光PVP手术具有出血少、尿管留置时间短、并发症少的特点.     

选择性激光前列腺汽化术治疗大体积前列腺增生82例的疗效及安全性观察

目的探讨选择性激光前列腺汽化术(PVP)治疗大体积前列腺增生(前列腺体积>100ml)患者的临床效果及安全性。方法回顾性分析82例体积>100ml的前列腺增生患者PVP治疗结果。结果所有患者前列腺平均体积176(110～340)ml,77例手术1次完成,5例手术分两次进行。所有患者术后排尿困难症状明显改善,国际前列腺症状评分(IPSS)由术前平均27.5分降至8.4分,生活质量(QOL)评分由4.6分降至2.1分,最大尿流率(Qmax)由4.9ml/s上升至19.0ml/s,残余尿量(RUV)由350ml降至110ml,均有统计学意义(P<0.01)。结论PVP是治疗体积>100ml前列腺增生患者的一种安全、有效的手术方法。     

经尿道钬激光剜除术治疗前列腺增生症

目的探讨经尿道钬激光剜除术治疗前列腺增生症的效果。方法采用钬激光前列腺剜除术治疗前列腺增生症50例,并对患者术前、术后的国际前列腺症状评分、生活质量评分及最大尿流率进行比较。结果手术后第3个月,国际前列腺症状评分,从手术前(2280±120)分降至(560±060)分,生活质量评分从手术前(480±072)分降至(150±009)分,最大尿流率从手术前(610±091)m1/s增加至(1730±183)ml/s,疗效显著。结论经尿道钬激光前列腺剜除术治疗前列腺增生症具有损伤小、术后恢复快和住院时间短等优点,具有良好的临床应用前景。     

双效能激光在前列腺增生症中的临床应用

目的:探讨1 470 nm双效能激光汽化术治疗良性前列腺增生症的临床疗效。方法:2016年7月至2017年6月,良性前列腺增生症患者52例,年龄60～82岁。应用1 470 nm双效能激光行激光汽化术。前列腺体积为36.5～62.6 ml,平均(42.3±6.6)ml,最大尿流率(7.8±2.4)ml/s,膀胱残余尿量(137.8±16.4)ml。观察与分析手术前后国际前列腺症状评分(IPSS)、生活质量评分(QOL)、最大尿流率(Qmax)、膀胱残余尿量(PVR)、手术时间、冲洗液颜色及用量、术前合并症及术后并发症,术后3～6个月进行随访评价疗效。结果:52例前列腺增生症患者1 470 nm双效能激光汽化术均获成功。术后IPSS评分、QOL评分、Qmax及PVR明显优于术前,经比较手术前后指标差异均有统计学意义(P﹤0.05)。手术时间20～82 min,平均(45±12)min。术中均未见明显出血。术后住院时间3～5 d,平均(3.5±1)d。结论:1 470 nm双效能激光汽化术是治疗中等大小前列腺增生患者安全有效的微创治疗方法,具有手术时间短、出血少、患者恢复快、住院时间缩短等优势。     

经尿道选择性绿激光汽化术与电切术治疗前列腺增生的价值比较

目的探讨经尿道选择性绿激光前列腺汽化术(PVP)治疗前列腺增生的安全性和疗效以及与经尿道前列腺电切术(TURP)相比的优势。方法对我院2003年10月—2007年9月行经尿道选择性绿激光汽化术患者75例(PVP组)及同期行经尿道前列腺电切术(TURP组,对照组)患者53例的临床资料(年龄,病程、术前IPSS、术前最大尿流率,术前残余尿、前列腺质量)、手术情况(手术时间,术后输血,术后尿管留置时间,术后住院时间)、疗效(术后最大尿流率,术后IPSS)等指标进行比较分析。结果两组年龄、病程、术前IPSS评分、术前最大尿流率、术前残余尿量等项指标之间的差异均无统计学意义(P>0.05)。PVP组前列腺质量(60.715±30.253)g,小于TURP组的(71.580±28.914)g(P=0.012 9)。两组手术后的IPSS以及最大尿流率较术前明显改善(P<0.01);而两组内手术前后的IPSS及最大尿流率比较,差异无统计学意义(P>0.05)。平均手术时间、术后输血、术后尿管留置时间、术后住院时间两组比较差异有统计学意义(P<0.05或P<0.01)。结论经尿道选择性绿激光汽化技术安全、疗效可靠,与传统的电切手术相比具有明显的优势,临床应用前景广阔。     

普通电切镜经尿道行前列腺剜除术治疗良性前列腺增生的疗效

目的 探讨以普通电切镜经尿道行前列腺剜除术(transurethral enucleative resection of prostate,TUERP)治疗良性前列腺增生(benign prostatic hyperplasia,BPH)的效果.方法 回顾性分析86例采用TUERP治疗BPH患者的临床资料,分别比较术前、术后国际前列腺症状评分(IPSS)、生活质量指数(QOL)、最大尿流率(Qmax)、残余尿量(PVR)情况.结果 手术均顺利完成,平均手术时间(62.7±19.3)min,切除腺体平均重量(37.2 ±8.5)g.术后IPSS由术前(23.9±5.2)分降至(5.4±3.7)分,QOL由术前(4.6±1.1)分降至(1.2±0.9)分,Qmax由术前(6.3±2.0)ml/s上升至(21.0±3.6) ml/s,PVR由术前(149.0±35.8)ml降至(21.2±9.9) ml.术后3例出现暂时性尿失禁,1例出现尿道外口狭窄,经治疗后痊愈.结论 TUERP术具有手术时间短、并发症少、术后恢复快、症状解除明显等优点,是治疗BPH的安全、有效的治疗方法.     

Knee injury and Osteoarthritis Outcome Score (KOOS) - validation of a Swedish version

The Knee injury and Osteoarthritis Outcome Score (KOOS) is a self-administered instrument measuring outcome after knee injury at impairment, disability, and handicap level in five subscales. Reliability, validity, and responsiveness of a Swedish version was assessed in 142 patients who underwent arthroscopy because of injury to the menisci, anterior cruciate ligament, or cartilage of the knee. The clinimetric properties were found to be good and comparable to the American version of the KOOS. Comparison to the Short Form-36 and the Lysholm knee scoring scale revealed expected correlations and construct validity. Item by item, symptoms and functional limitations were compared between diagnostic groups. High responsiveness was found three months after arthroscopic partial meniscectomy for all subscales but Activities of Daily Living.     

Endovascular management of carotid-cavernous fistulas

Objective To investigate endovascular treatment of traumatic direct carotid-cavernous fistulas （CCF） and their complications such as pseudoaneurysms. Methods： Over a five-year period, 22 patients with traumatic direct CCFs were treated endovascularly in our institution. Thirteen patients were treated once with the result of CCF occluded, 8 twice and 1 three times. Treatment modalities included balloon occlusion of the CCF, sacrifice of the ipsilateral internal carotid artery with detachable balloon, coll embolization of the cavernous sinus and secondary pseudoaneurysms, and covered-stem management of the pseudoaneurysms. Results All the direct CCFs were successfully managed endovascularly. Four patients developed a pseudoaneurysm after the occlusion of the CCF with an incidence of pseudoaneurysm formation of 18.2% （4/22）. A total number of 8 patients experienced permanent occlusion of the ICA with a rate of ICA occlusion reaching 36.4% （8/22）. Followed up through telephone consultation from 6 months to 5 years, all did well with no recurrence of CCF symptoms and signs. Conclusion Traumatic direct CCFs can be successfully managed with endovascular means. The pseudoaneurysms secondary to the occlusion of the CCFs can be occluded with stent-assisted coiling and implantation of covered stents.     

The acutely limping child

Acute limping may be the result of multiple pathologies in children. The differential diagnosis varies based on the age of the child. Irrespective of age, the initial imaging work-up includes AP and frog leg radiographs of the pelvis and ultrasound; MRI may sometimes be helpful. In children less than 3 years, infections and trauma are most frequent. MRI is the imaging modality of choice when osteomyelitis is clinically suspected. Between the ages of 3 and 10 years, transient synovitis of the hip and Legg-Calvé-Perthes disease are main considerations but infection, inflammation and focal bony lesions are also considered. In children over 10 years, slipped capital femoral epiphysis also is considered.     

Do Balance Board Training Programs Reduce the Risk of Ankle Sprains in Athletes?

Introduction Ankle sprains are the most common musculo-skeletal injury that occurs in athletes,particularly in sports that require jumping and landing on one foot such as soccer,and basketball(1-4).These injuries often result in significant time loss from participation,long-term disability,and have a major impact on health care costs and resources(5-8).     

High Intensity Interval Training:New Insights

KEY POINTS ·High-intensity interval training(HIT)is characterized by repeated sessions of relatively brief，intermittent exercise.often performed with an“a11 out”effort or at an intensity close to that which elicits peak oxygen uptake(i.e.，≥90%of VO2 peak).     

Developmental validation of the PowerPlex(®) ESI 16 and PowerPlex(®) ESI 17 Systems: STR multiplexes for the new European standard

In response to the ENFSI and EDNAP groups’ call for new STR multiplexes for Europe, Promega^® developed a suite of four new DNA profiling kits. This paper describes the developmental validation study performed on the PowerPlex^® ESI 16 (European Standard Investigator 16) and the PowerPlex^® ESI 17 Systems. The PowerPlex^® ESI 16 System combines the 11 loci compatible with the UK National DNA Database^®, contained within the AmpFlSTR^® SGM Plus^® PCR Amplification Kit, with five additional loci: D2S441, D10S1248, D22S1045, D1S1656 and D12S391. The multiplex was designed to reduce the amplicon size of the loci found in the AmpFlSTR^® SGM Plus^® kit. This design facilitates increased robustness and amplification success for the loci used in the national DNA databases created in many countries, when analyzing degraded DNA samples. The PowerPlex^® ESI 17 System amplifies the same loci as the PowerPlex^® ESI 16 System, but with the addition of a primer pair for the SE33 locus. Tests were designed to address the developmental validation guidelines issued by the Scientific Working Group on DNA Analysis Methods (SWGDAM), and those of the DNA Advisory Board (DAB). Samples processed include DNA mixtures, PCR reactions spiked with inhibitors, a sensitivity series, and 306 United Kingdom donor samples to determine concordance with data generated with the AmpFlSTR^® SGM Plus^® kit. Allele frequencies from 242 white Caucasian samples collected in the United Kingdom are also presented. The PowerPlex^® ESI 16 and ESI 17 Systems are robust and sensitive tools, suitable for the analysis of forensic DNA samples. Full profiles were routinely observed with 62.5 pg of a fully heterozygous single source DNA template. This high level of sensitivity was found to impact on mixture analyses, where 54–86% of unique minor contributor alleles were routinely observed in a 1:19 mixture ratio. Improved sensitivity combined with the robustness afforded by smaller amplicons has substantially improved the quantity of data obtained from degraded samples, and the improved chemistry confers exceptional tolerance to high levels of laboratory prepared inhibitors.